Tailored high-content assays, method development, and efficacy evaluations tailored to meet Dutch Health and Youth Care Inspectorate (IGJ) and EU regulatory expectations.
The Netherlands stands at the global forefront of life science innovation, biopharmaceuticals, and sustainable food research. Clusters such as the Leiden Bio Science Park, Food Valley Wageningen, Utrecht Science Park, and the Amsterdam BioMed Cluster generate intense demand for highly accurate, reproducible, and animal-free cell-based testing models. Driven by the Dutch National Committee for the protection of animals used for scientific purposes (NCad) and EU directive mandates, Dutch research institutions and pharmaceutical entities are actively accelerating the adoption of New Approach Methodologies (NAMs).
In this fast-evolving landscape, traditional testing paradigms are being replaced by high-throughput 2D/3D human cell cultures, organoid assays, microfluidic gut-on-a-chip models, and high-content imaging profiling. Dutch health-tech startups, cosmetics developers, and functional food innovators require rapid assay prototyping, mechanistic toxicity screening, and bio-activity validation without compromising regulatory compliance under the European Medicines Agency (EMA) and the European Chemicals Agency (ECHA).
MedGence Technical Co., Ltd. (Yineng Pharma) bridges the gap between early-stage bio-assay discovery and commercial manufacturing scale. By supplying robust, custom-engineered in vitro assay services to Dutch research hubs, we empower life science leaders to de-risk candidate molecules, validate botanical extracts, and secure validated batch profiling at fraction of Western European contract costs.
Our cell biology laboratories integrate modern analytical chemistry with high-content automated screening to provide Dutch clients with multi-dimensional bio-activity data.
Rapid screening using MTT, CCK-8, LDH release, and ATP luminescence across standardized human cell lines (HepG2, Caco-2, HaCaT, RAW 264.7) to determine IC50, CC50, and safe therapeutic windows for complex botanical mixtures.
Quantification of key pro-inflammatory cytokine suppression (TNF-α, IL-1β, IL-6, IL-8, PGE2, NO) via ELISA and multiplex bead assays, validating anti-inflammatory claims for phytopharmaceuticals and functional ingredients.
Full compliance with EU Regulation EC 1223/2009 for skin irritation, corrosion (OECD 431/439 using reconstructed human epidermis), melanin inhibition (tyrosinase activity), collagen synthesis, and anti-photoaging screening.
Evaluation of ROS scavenging capacity, SOD activity, DPPH/ABTS radical neutralization, glucose uptake enhancement in 3T3-L1 adipocytes, and lipid accumulation inhibition in NAFLD cellular models.
Utilizing Caco-2 cell monolayer models to measure Transepithelial Electrical Resistance (TEER) and apparent permeability coefficients (Papp), assessing nutrient uptake and gut-barrier transport in Wageningen Food Valley projects.
Automated microscopic analysis tracking organelle morphology, nuclear translocation, mitochondrial membrane potential (JC-1), and apoptosis progression, yielding statistical depth for drug discovery filings.
How MedGence (Yineng Pharma) provides Dutch partners with unparalleled scalability, cost competitiveness, and scientific speed.
China houses over 12,000 documented medicinal plant species. MedGence maintains direct regional sourcing networks, allowing precise evaluation of bioactive compound variations based on seasonal harvest windows, soil mineralogy, and altitude.
Unlike standalone testing labs, our Changsha R&D center is backed by pilot extraction plants and GMP-compliant commercial production facilities. Validated lab assay protocols transition smoothly into multi-ton batch processing without tech-transfer friction.
European CROs face soaring energy costs and prolonged lead times. Our automated high-throughput assays reduce testing cycles by up to 60%, delivering comprehensive GLP-ready analytical dossiers at highly optimized price points.
Understanding when to deploy high-throughput cell assays versus animal models is crucial for Dutch biotech entrepreneurs seeking EMA alignment, cost reduction, and ethical approval speed.
| Evaluation Parameter | In Vitro Cell Assays (MedGence Platform) | Traditional In Vivo Animal Models | Dutch Regulatory Impact (EU/EMA) |
|---|---|---|---|
| Testing Lead Time | 2 to 4 Weeks | 3 to 9 Months | Accelerates Early Pipeline Decisions |
| Ethical Approval (3Rs) | No Animal Use Required | Extensive DEC / CCD Review Needed | Fully Aligned with Dutch NCad Mandates |
| Cost Efficiency | High (Automated Parallel Multi-Plates) | Low (Husbandry, Maintenance, Ethics) | Optimizes Preclinical R&D Expenditure |
| Mechanistic Precision | Direct Molecular Pathway Target Isolation | Complex Systemic Interaction | Provides High-Content Proof of Action |
| Batch Consistency QC | Ideal for Routine Botanical Extract Lot Control | Unsuitable for Quality Control Release | Required for EU IVDR & Novel Food Filings |
Compliance is non-negotiable when exporting botanical ingredients or submitting safety data packages to Dutch authorities. MedGence maintains an uncompromising quality culture aligned with European standards.
Need to establish analytical method parameters, perform cytotoxicity screening, or submit a custom OECD 439 dossier?
Our scientific directors review your targets under full NDA within 24 business hours.
Send Inquiry NowSelect from our standard contract services or request custom protocol development for your target market in the Netherlands and Europe.
Expert guidance addressing regulatory pathways, sample submission, quality assurance, and contract research workflow.
We offer a full panel of OECD-validated in vitro assays, including reconstructed human tissue models (skin/ocular irritation OECD 439/431), 2D/3D human primary cell cultures, and microfluidic Caco-2 gut barrier models. These animal-free paradigms provide actionable bio-efficacy and toxicology data that comply with Dutch NCad goals and EU REACH/Cosmetics standards.
Every research project concludes with a comprehensive GLP-ready technical dossier. This includes raw spectroscopic/photometric data, calibration curves, IC50/EC50 determinations, HPLC/HPTLC fingerprint chromatograms, statistical standard deviation analysis, and a signed Certificate of Analysis (CoA) suitable for regulatory submission to EU bodies.
Yes. Botanical active concentration fluctuates significantly due to geographic origin, soil chemistry, climate, and harvesting season. We perform multi-batch analytical finger-printing coupled with in vitro functional assays to establish optimal sourcing windows and standardize target compound content for consistent commercial production.
We maintain streamlined international sample shipping protocols via express logistics (DHL/FedEx/TNT) with temperature-controlled packaging (ambient, +4°C, dry ice -78.5°C). We assist Dutch clients with customs documentation and biological material declaration forms to guarantee swift import customs clearance in China.
We operate strictly on an entrusted contract research basis. Before exchanging any chemical structures, plant strain data, or formulation details, we execute a legally binding Non-Disclosure Agreement (NDA). All project data and process parameters remain the exclusive intellectual property of the client.
Absolutely. MedGence integrates early-stage CRO assay discovery directly with CDMO scale-up facilities. Once an active extract or formulation proves effective in cell assays, our process engineering team optimizes extraction yield, concentration, spray drying, and dosage formulation (capsules, tablets, oral liquids, powders) for commercial manufacturing.
Partner with a trusted natural medicine CRO & CDMO offering high-throughput assay screening, validated analytical method establishment, and seamless commercial supply.
